These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23689710)

  • 41. Enfuvirtide: the first HIV fusion inhibitor.
    Lazzarin A
    Expert Opin Pharmacother; 2005 Mar; 6(3):453-64. PubMed ID: 15794736
    [TBL] [Abstract][Full Text] [Related]  

  • 42. gp41 sequence variability in HIV type 1 non-B subtypes infected patients undergoing enfuvirtide pressure.
    D'Arrigo R; Ciccozzi M; Gori C; Montieri S; Aquaro S; Bellagamba R; Boumis E; Di Perri G; Pizzi D; Antinori A; Rezza G; Perno CF
    AIDS Res Hum Retroviruses; 2007 Oct; 23(10):1296-302. PubMed ID: 17961119
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Amino acid conservation in the gp41 transmembrane protein and natural polymorphisms associated with enfuvirtide resistance across HIV-1 variants.
    Holguín A; De Arellano ER; Soriano V
    AIDS Res Hum Retroviruses; 2007 Sep; 23(9):1067-74. PubMed ID: 17919099
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enfuvirtide: antiretroviral class 4, drug 1.
    Asboe D
    HIV Clin Trials; 2004; 5(1):1-6. PubMed ID: 15002081
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.
    Champagne K; Shishido A; Root MJ
    J Biol Chem; 2009 Feb; 284(6):3619-27. PubMed ID: 19073602
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations.
    Marcial M; Lu J; Deeks SG; Ziermann R; Kuritzkes DR
    J Clin Microbiol; 2006 Sep; 44(9):3384-7. PubMed ID: 16954280
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: fitness tampering or a case of persistent braking on entering?
    Morse C; Maldarelli F
    J Infect Dis; 2007 Feb; 195(3):318-21. PubMed ID: 17205468
    [No Abstract]   [Full Text] [Related]  

  • 48. Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy.
    Charpentier C; Jenabian MA; Piketty C; Karmochkine M; Tisserand P; Laureillard D; Bélec L; Si-Mohamed A; Weiss L
    Scand J Infect Dis; 2011 May; 43(5):373-9. PubMed ID: 21341978
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART.
    Moyle G
    J Antimicrob Chemother; 2003 Feb; 51(2):213-7. PubMed ID: 12562683
    [No Abstract]   [Full Text] [Related]  

  • 50. Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.
    Yu D; Ding X; Liu Z; Wu X; Zhu Y; Wei H; Chong H; Cui S; He Y
    J Biol Chem; 2018 Aug; 293(33):12703-12718. PubMed ID: 29929981
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
    Labrosse B; Morand-Joubert L; Goubard A; Rochas S; Labernardière JL; Pacanowski J; Meynard JL; Hance AJ; Clavel F; Mammano F
    J Virol; 2006 Sep; 80(17):8807-19. PubMed ID: 16912327
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The current progress in the development of HIV-1 fusion inhibitors].
    Shi WG; Jia QY; Liu KL
    Yao Xue Xue Bao; 2010 Feb; 45(2):184-93. PubMed ID: 21351428
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Artificial peptides conjugated with cholesterol and pocket-specific small molecules potently inhibit infection by laboratory-adapted and primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains.
    Wang C; Shi W; Cai L; Lu L; Yu F; Wang Q; Jiang X; Xu X; Wang K; Xu L; Jiang S; Liu K
    J Antimicrob Chemother; 2014 Jun; 69(6):1537-45. PubMed ID: 24500189
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice.
    Stoddart CA; Nault G; Galkina SA; Thibaudeau K; Bakis P; Bousquet-Gagnon N; Robitaille M; Bellomo M; Paradis V; Liscourt P; Lobach A; Rivard ME; Ptak RG; Mankowski MK; Bridon D; Quraishi O
    J Biol Chem; 2008 Dec; 283(49):34045-52. PubMed ID: 18809675
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.
    Su Y; Chong H; Xiong S; Qiao Y; Qiu Z; He Y
    J Virol; 2015 Dec; 89(24):12467-79. PubMed ID: 26446597
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increasing hydrophobicity of residues in an anti-HIV-1 Env peptide synergistically improves potency.
    Leung MY; Cohen FS
    Biophys J; 2011 Apr; 100(8):1960-8. PubMed ID: 21504732
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
    Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S
    Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro.
    Su C; Melby T; DeMasi R; Ravindran P; Heilek-Snyder G
    J Clin Virol; 2006 Aug; 36(4):249-57. PubMed ID: 16765082
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor.
    Liu Z; Shan M; Li L; Lu L; Meng S; Chen C; He Y; Jiang S; Zhang L
    J Biol Chem; 2011 Feb; 286(5):3277-87. PubMed ID: 21098485
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.
    Dwyer JJ; Wilson KL; Davison DK; Freel SA; Seedorff JE; Wring SA; Tvermoes NA; Matthews TJ; Greenberg ML; Delmedico MK
    Proc Natl Acad Sci U S A; 2007 Jul; 104(31):12772-7. PubMed ID: 17640899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.